Vera Therapeutics (VERA) Other Non-Current Liabilities (2020 - 2026)

Vera Therapeutics has reported Other Non-Current Liabilities for 7 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (changed N/A YoY), and the FY2025 full-year result was $1.9 million, changed N/A from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $1.9 million, down from $1.9 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $1.9 million in Q4 2025, with the low at $286000.0 in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $553666.7 across 5 years, with a median of $286000.0 in 2022.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities sank 80.07% — and 2023, when it grew 0.35%.
• Vera Therapeutics' Other Non-Current Liabilities stood at $286000.0 in 2022, then changed by 0.0% to $286000.0 in 2023, then changed by 0.0% to $286000.0 in 2024, then surged by 570.98% to $1.9 million in 2025, then slipped by 2.87% to $1.9 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $286000.0 (Q2 2024), per Business Quant data.